Literature DB >> 16211124

Cardiac findings in children admitted to a hospital general ward in South Africa: a comparison of HIV-infected and uninfected children.

S C Brown1, C J Schoeman, C J Bester.   

Abstract

The aim of this prospective observational study was to determine the presence of cardiac abnormalities in HIV infected versus uninfected children who were admitted to a general paediatric ward during a two-month period. HIV status was determined by antibody and p24 antigen testing. Clinical information, echocardiography and electrocardiography (ECG) were performed for all children. There were 90 HIV-infected and 118 uninfected children. The median age was 9.6 and 11.8 months for infected and uninfected children, respectively. Baseline left ventricular dysfunction, defined as a shortening fraction < or = 25%, was found in 13 (17%) of the HIV-infected children compared to 5 (8%) uninfected children (p < 0.05). Left ventricular end-diastolic enlargement above the 98th percentile for age was found in 24% of the infected and 20% of uninfected children. Pericardial effusions, although common, were sub-clinical and not different in the groups. ECG findings and resting heart rates were also similar. Left ventricular dysfunction was the most significant cardiac abnormality present in hospitalised HIV-infected children. Other abnormalities, although common, were mostly asymptomatic and found with the same frequency in uninfected children. Further studies are indicated.

Entities:  

Mesh:

Year:  2005        PMID: 16211124

Source DB:  PubMed          Journal:  Cardiovasc J S Afr


  9 in total

1.  Cardiac manifestations in HIV infected children.

Authors:  Pradeep Singh; Alok Hemal; Sheetal Agarwal; Dinesh Kumar
Journal:  Indian J Pediatr       Date:  2014-05-25       Impact factor: 1.967

Review 2.  Perinatally acquired HIV infection in adolescents from sub-Saharan Africa: a review of emerging challenges.

Authors:  Elizabeth D Lowenthal; Sabrina Bakeera-Kitaka; Tafireyi Marukutira; Jennifer Chapman; Kathryn Goldrath; Rashida A Ferrand
Journal:  Lancet Infect Dis       Date:  2014-01-07       Impact factor: 25.071

3.  The impact of HAART on cardiomyopathy among children and adolescents perinatally infected with HIV-1.

Authors:  Kunjal Patel; Russell B Van Dyke; Murray A Mittleman; Steven D Colan; James M Oleske; George R Seage
Journal:  AIDS       Date:  2012-10-23       Impact factor: 4.177

4.  Echocardiographic abnormalities in children and adolescents living with human immunodeficiency virus on highly active antiretroviral treatment.

Authors:  Tewolde Wubayehu; Workeabeba Abebe; Endale Tefera
Journal:  Cardiovasc J Afr       Date:  2020-02-05       Impact factor: 1.167

5.  Getting to 90-90-90 in paediatric HIV: What is needed?

Authors:  Mary-Ann Davies; Jorge Pinto; Marlène Bras
Journal:  J Int AIDS Soc       Date:  2015-12-02       Impact factor: 5.396

Review 6.  Universal antiretroviral therapy for HIV-infected children: a review of the benefits and risks to consider during implementation.

Authors:  Linda Barlow-Mosha; Victor Musiime; Mary-Ann Davies; Andrew J Prendergast; Philippa Musoke; George Siberry; Martina Penazzato
Journal:  J Int AIDS Soc       Date:  2017-06-27       Impact factor: 5.396

7.  ECG abnormalities among HIV infected children placed on ART at Enugu, South East of Nigeria.

Authors:  Emeka Spiff Eleazar; Clara Idara Eleazar; Daniel Chukwu Nwachukwu; Uchenna Ifeanyi Nwagha
Journal:  Afr Health Sci       Date:  2020-12       Impact factor: 0.927

8.  Cardiac disease in adolescents with delayed diagnosis of vertically acquired HIV infection.

Authors:  Robert F Miller; Juan P Kaski; James Hakim; Jonathan Matenga; Kusum Nathoo; Shungu Munyati; Sujal R Desai; Elizabeth L Corbett; Rashida A Ferrand
Journal:  Clin Infect Dis       Date:  2012-10-24       Impact factor: 9.079

9.  The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected children.

Authors:  Rachel C Vreeman; Michael L Scanlon; Megan S McHenry; Winstone M Nyandiko
Journal:  J Int AIDS Soc       Date:  2015-12-02       Impact factor: 5.396

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.